- Report
- April 2025
- 200 Pages
Global
From €4096EUR$4,490USD£3,501GBP
- Report
- May 2024
- 130 Pages
Global
From €5929EUR$6,499USD£5,067GBP
- Report
- May 2024
- 138 Pages
Global
From €5929EUR$6,499USD£5,067GBP
- Report
- May 2024
- 135 Pages
Global
From €5929EUR$6,499USD£5,067GBP
- Report
- October 2024
- 331 Pages
Global
From €7252EUR$7,950USD£6,199GBP
- Report
- March 2024
- 159 Pages
Global
From €7252EUR$7,950USD£6,199GBP
- Report
- April 2023
- 147 Pages
Global
From €4515EUR$4,949USD£3,859GBP
- Report
- November 2023
- 171 Pages
Global
From €4105EUR$4,500USD£3,509GBP
- Report
- August 2022
- 51 Pages
Global
From €1824EUR$2,000USD£1,559GBP
- Report
- April 2025
- 50 Pages
Global
From €2417EUR$2,650USD£2,066GBP
- Book
- January 2010
- 616 Pages
Amiodarone is a medication used to treat irregular heartbeats and other cardiac arrhythmias. It is a class III antiarrhythmic drug, and is one of the most commonly prescribed drugs in the cardiovascular drug market. It works by blocking certain electrical signals in the heart, which helps to regulate the heart rate. Amiodarone is used to treat a variety of conditions, including atrial fibrillation, ventricular tachycardia, and ventricular fibrillation. It is also used to prevent recurrent episodes of atrial fibrillation and ventricular tachycardia.
Amiodarone is available in both oral and intravenous forms, and is generally well tolerated. Common side effects include nausea, vomiting, and dizziness. More serious side effects can include liver damage, thyroid problems, and pulmonary toxicity.
The amiodarone market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Sanofi, GlaxoSmithKline, and Merck. Show Less Read more